WOBURN, MA– International life sciences firm Minovia Therapeutics is expanding its U.S. operations from Kendall Square in Cambridge to include a 4,600-square-foot facility in Woburn’s growing technology cluster.
The venture-backed company is slated to commence its GMP cell therapy manufacturing at 12 Gill Street, a Cummings Properties building, this fall.
Founded in 2012, the Israeli-based firm is developing a cell therapy approach to treat rare mitochondrial diseases. Minovia’s proprietary Mitochondrial Augmentation Therapy (MAT) platform was developed as a means to treat rare pediatric diseases, such as Pearson Syndrome, as well as other indications in the future.
“The location and existing buildout of the space make it ideal for Minovia’s operations,” said Minovia Therapeutics owner’s representative Ed Dondero.
Senior Leasing Director Rob Yacobian of Cummings Properties worked with Cushman & Wakefield executive managing director Ted Lyon on the lease.
“A growing number of urban firms are realizing that a thriving science hub and significant cost savings await them along the 128 belt just north of the city,” said Yacobian. “The Gill Street site offers Minovia a convenient, visually appealing setting in an established biotech community that continues to evolve.”
Among the life sciences firms located at 12 Gill Street are ReForm Biologics, Unchained Labs, and fellow Cambridge transplant Farcast Biosciences (formerly known as Mitra RxDx). Other new neighbors in the industry include Amgen, Azurity Pharmaceuticals, Covaris, Bio2 Technologies, Genturi, Modular Genetics, and Verdox.
Minovia’s new space will include a mix of office and lab space. The firm is constructing a state-of-the-art pharmaceutical clean room in the suite.
